Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021
Daxor Corporation (NYSE: DXR), a leader in blood volume measurement technology, announces that CEO Michael Feldschuh will present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021, at 4:30 PM ET. He will discuss Daxor's business model, growth strategy, and next-generation technology. The event will be virtual, allowing investors to register for attendance or request one-on-one meetings. The presentation will be available for live streaming and replay on Daxor's website.
- None.
- None.
NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that Michael Feldschuh, Daxor’s President and Chief Executive Officer will present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 2, 2021 at 4:30 PM ET.
Mr. Feldschuh will provide an overview of the company’s business model, growth strategy, and next generation technology. To receive additional information, request an invitation or to schedule a one-on-one meeting, email angie.goertz@issuerdirect.com.
Investors can register here.
The presentation will be webcast live and available for replay at: Daxor.
About the MicroCap Rodeo Summer Solstice Best Ideas Conference
The MicroCap Rodeo is back with its third "Best Ideas Bowl." This conference is a virtual conference that brings the top 35 best ideas from the buy side. Qualified institutional investors recommended each of the 35 companies represented as one of their best ideas.
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com
FAQ
When will Daxor's CEO present at the Summer Solstice Conference?
What topics will be covered in Daxor's presentation at the conference?
How can investors register for Daxor's presentation?
Will Daxor's presentation be available for replay?
What is the purpose of the MicroCap Rodeo Summer Solstice Conference?
